Management of ruxolitinib failure in myelofibrosis

John Mascarenhas, MD, Icahn School of Medicine at Mount Sinai, New York, NY, provides insights into the management of patients who fail ruxolitinib treatment. To begin with, patients treated with ruxolitinib who have residual transfusion burden can receive various agents in addition to ruxolitinib. Patients who have poorly controlled spleen and symptom burden and anemia should switch from ruxolitinib to another agent like fedratinib, and patients who are transplant-eligible should be referred for transplantation. In addition, patients also have the opportunity to enroll in clinical trials evaluating novel agents for MF, including pelabresib, navitoclax, parsaclisib, and navtemadlin. This interview took place virtually.